KAND567 Versus Placebo in Subjects Hospitalized With COVID-19

Summary

The study is a phase II, randomized, 2-arm parallel-group, double-blind study to explore the efficacy, safety, tolerability and pharmacokinetics of KAND567 versus placebo in COVID-19 subjects in need of oxygen treatment. The target was to include forty (40) subjects with diagnosed COVID-19 for participation in the study. If at screening all criteria for study participation were fulfilled and informed consent signed, the subject was enrolled and randomized into one of the two arms. After randomization, the subjects were to receive KAND567 or placebo treatment for 7 days. After the treatment period the subjects returned to ordinary clinical follow-up, but a study follow-up visit was to be planned for Day 21 and 90.

Timeline

Start

2020-10-11

Primary completion

2021-08-07

Completion

2021-08-07

Outcome

Outcome not reported

Stopped (Enrollment): “Slow recruitment”

Drugs

Indications